Tumor suppressor gene

From WikiLectures


Tumor suppressor genes' (also called anti-oncogenes or recessive oncogenes) have an essential role in the malignant process. Their products regulate cell division. The loss of both alleles of a certain suppressor gene (e.g. deletion), a change in their structure (e.g. point mutation) leads to a disorder of cell cycle control ) or inactivation of the protein encoded by them. All this can result in a malignant transformation of the cell.

General[edit | edit source]

The principle of the two-hit theory in retinoblastoma

Mutations in tumor suppressor genes have a ``recessive character. Unlike oncogenes, proteins encoded by anti-oncogenes have an antiproliferative effect, promote differentiation and apoptosis.

There are about 40 tumor suppressor genes in each somatic cell. To become tumorigenic, both of their alleles must be mutated – hence the name recessive oncogenes. This is related to the so-called double hit theory (first formulated by Knudson when explaining the occurrence of rare hereditary retinoblastoma). In contrast to the much more common sporadic retinoblastoma, where there are random mutations of one and then the other allele in the retinal cell, in the hereditary form one mutated allele is inherited. The relevant individual is a heterozygote in whom the inherited tumor predisposition is not yet manifested. However, if the second allele is mutated/eliminated, the development of a tumor clone of retinal cells is initiated.

This process is called ``loss of heterozygosity (LOH – loss of heterozygosity).

pRB[edit | edit source]

The CDK4/Cyclin D complex phosphorylates the pRB/E2F complex and thereby releases the E2F transcription factor, which further enables the cell to transition from G1 to S phase The first discovered tumor suppressor gene was called the retinoblastoma gene (RB1 gene)' and its product RB-protein (pRB). It occurs in every cell, where it regulates the cell division cycle.

Retinoblastoma gene (RB1) and another tumor suppressor gene TP53, respectively. their products act as a kind of brake on cell proliferation. RB1 negatively regulates the important transcription factor E2F. Deletion of the ``RB1 gene, which occurs in hereditary retinoblastoma, or sequestration of its protein product in the presence of adenoviral protein E1A or protein E7 (in human papillomavirus infection) induces unblocking of E2F suppression. In contrast, p53 acts by promoting the expression of p21/CIP, which is a potent inhibitor of cell cycle-regulating kinases (cyclin-dependent kinases).

Loss of the regulatory function of the Rb gene in the cell cycle or overexpression of c-myc leads to increased proliferation, but also to increased apoptosis of the affected cells. Virogenic products such as E1A (adenovirus infection), T121-antigen' (from SV-virus) or E7 (from human papillomavirus) bind to Rb and then have a similar effect. At this stage, the number of transformed cells does not increase yet. However, another genetic change, causing loss of p19ARF, mutation of p53, or overexpression of bcl-2, leads to increased proliferation and reduced apoptosis. Contributing to this are gene products such as E1b (from adenovirus), large antigen from SV-virus and E-6 antigen from papillomavirus, which bind to the p53 protein. Apoptosis, or the tendency to decrease it, is of key importance for the development of tumorigenesis.

p53[edit | edit source]

The tumor suppressor gene TP53, which encodes the protein p53, is a key regulatory factor that monitors DNA damage. Inactivation of p53 is usually one of the first steps that leads to malignant transformation in the development of a number of cancer diseases. Patients with Li-Fraumeni syndrome usually have one mutant allele in their germ cells and thus an increased risk of developing sarcomas, leukemia and carcinoma of the mammary gland] .

Located on the short arm of chromosomeu 17 (17p13.1, OMIM: 191170), contains 393 codons, regulates the course of interphase, also called "guardian of the genome" . It reacts to DNA damage by temporarily suspending the cycle and thus enables error repair (the so-called big repair). Cave!!!.png It controls the initiation and duration of the quiescent stage through genes whose transcriptional activity is controlled by its p53 protein.

The p53 gene is also used in the 2nd interphase checkpoint - by pausing the cell cycle in this period, it enables the so-called post-replication repair. Furthermore, it induces and coordinates apoptosis when DNA repair is not successful. P53 pathways

Overview of some recessive oncogenes causing cancer
Symbol Name Cancer disease
APC Adematous polyposis colon gene Colorectal carcinoma
BRCA1 Family Breast/Ovarian Cancer Gene 1 Hereditary Breast/Ovarian Cancer
BRCA2 Family Breast/Ovarian Cancer Gene 2 Hereditary Breast/Ovarian Cancer
CDH1 Cadherin 1 gene Familial gastric cancer, lobular breast cancer
CDNK2A Cyclin-dependent kinase 2A inhibitor gene (p16) Malignant melanoma of the skin
EP300 300 kD-E1A binding protein gene Colorectal, pancreatic, breast carcinomas


Links[edit | edit source]

Source[edit | edit source]

  • {{#switch: web

|book =

  Incomplete publication citation. ŠTEFÁNEK, GeorgeAlso available from <https://www.stefajir.cz/>. 

|collection =

  Incomplete citation of contribution in proceedings. ŠTEFÁNEK, George. Also available from <https://www.stefajir.cz/>. {{
  #if:  |978-80-7262-438-6} }
  |article = 
  Incomplete article citation.  ŠTEFÁNEK, George. Medicine, diseases, studies at the 1st Faculty of Medicine, UK. also available from <https://www.stefajir.cz/>. 

|web =

  ŠTEFÁNEK, George. Medicine, diseases, studies at the 1st Faculty of Medicine, UK [online]. [cit. 2010-02-11]. <https://www.stefajir.cz/>.

|cd =

  ŠTEFÁNEK, George. Medicine, diseases, studies at the 1st Faculty of Medicine, UK [CD/DVD]. [cit. 2010-02-11]. 

|db =

  Incomplete database citation. Medicine, diseases, studies at the 1st Faculty of Medicine, UK [database]. [cit. 2010-02-11]. <https://www.stefajir.cz/>.

|corporate_literature =

  Incomplete citation of company literature. ŠTEFÁNEK, George. Also available from <https://www.stefajir.cz/>. legislative_document = 
  Incomplete citation of legislative document.  Also available from URL <https://www.stefajir.cz/>.


  • {{#switch: web

|book =

  Incomplete publication citation. MASOPUST, Jaroslav. Pathobiochemistry of cells [online] . 2003. Also available from <http://dotdiag.cz/img/prednasky/bunka.pdf>. 

|collection =

  Incomplete citation of contribution in proceedings. MASOPUST, Jaroslav. Pathobiochemistry of cells [online] . 2003. Also available from <http://dotdiag.cz/img/prednasky/bunka.pdf>. {{
  #if:  |978-80-7262-438-6} }
  |article = 
  Incomplete article citation.  MASOPUST, Jaroslav. 2003, year 2003, also available from <http://dotdiag.cz/img/prednasky/bunka.pdf>. 

|web =

  Incomplete site citation. MASOPUST, Jaroslav. ©2003. [cit. 2011-03-17]. <http://dotdiag.cz/img/prednasky/bunka.pdf>.

|cd =

  Incomplete carrier citation. MASOPUST, Jaroslav. ©2003. [cit. 2011-03-17]. 

|db =

  Incomplete database citation. ©2003. [cit. 2011-03-17]. <http://dotdiag.cz/img/prednasky/bunka.pdf>.

|corporate_literature =

  Incomplete citation of company literature. MASOPUST, Jaroslav. Pathobiochemistry of cells [online] . 2003. Also available from <http://dotdiag.cz/img/prednasky/bunka.pdf>. legislative_document = 
  Incomplete citation of legislative document.  2003. Also available from URL <http://dotdiag.cz/img/prednasky/bunka.pdf>.


Template:Stump